CHST13

Across TCGA pan-cancer cohorts, CHST13 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CHST13 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CHST13 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHST13 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

HNSC, LIHC, and LUSC are the cancer types where CHST13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.117	0.697	<.001	57	view →
LIHC	OS	Median	All	0.067	0.781	<.001	12	view →
LUSC	OS	Median	II,III,IV	0.073	0.743	<.001	12	view →
PRAD	DFS	Median	All	0.141	0.777	<.001	6	view →
GBM	DFS	Median	All	1.000	0.192	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CHST13–HNSC (DFS)

Open the HNSC breakdown →